Evidence map›Paper›PMID 42714795›Full record

ArticleScience China. Life sciences2026

Targeting KRAS reprograms a Treg-dominant immunosuppressive microenvironment and sensitizes KRAS-mutant gastric adenocarcinoma to CTLA-4 immunotherapy.

Xiaohuan Tang, Peiyao Yang, Xiaoyong Guo, Shuhua Wei, Xiaojing Cheng, Mengyuan Li, Yigang Bao, Sachiyo Nomura, Yu Sun, Longtao Huangfu and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xiaohuan Tang *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Ward I, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Peiyao Yang *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Ward I, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Xiaoyong Guo *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Ward I, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Shuhua Wei *Department of Radiation Oncology, Peking University Third Hospital, Beijing, 100191, China.
Xiaojing Cheng *Biological sample bank, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Mengyuan LiDepartment of Radiation Oncology, China-Japan Friendship Hospital, Beijing, 100142, China.
Yigang BaoDepartment of Cancer Biology and Molecular Medicine, Cancer Center and Beckman Research Institute, City of Hope, Duarte, CA, 91010, USA.
Sachiyo NomuraDepartment of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8654, Japan.
Yu SunDepartment of Pathology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Longtao HuangfuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Ward I, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Xiaofang XingKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Ward I, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Yongning JiaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Ward I, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Fei ShanKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Ward I, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Xiangyu GaoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Ward I, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China. xiangyugao@hsc.pku.edu.cn.
Chuanhui HanState Key Laboratory of Molecular Oncology, Frontiers Science Center for Cancer Integrative Omics, Peking University Cancer Hospital & Institute, Peking University International Cancer Institute, Peking University Health Science Center, Beijing, 100191, China. chuanhui.han@bjmu.edu.cn.
Ziyu LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Ward I, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, 100142, China. ziyu_li@hsc.pku.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncogenic KRAS mutations define a distinct molecular subset of gastric adenocarcinoma (GA), yet their impact on the tumor immune microenvironment remains incompletely understood. In this study, we established a genetically faithful and immunocompetent KRAS

Indexed as

gastric adenocarcinomaKRAS mutationtargeted immunotherapyTGF-β+ Tregtumor microenvironment

Identifiers

PMID42714795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.